| Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ... American journal of respiratory and critical care medicine 190 (2), 175-184, 2014 | 401 | 2014 |
| SpiroSmart: using a microphone to measure lung function on a mobile phone EC Larson, M Goel, G Boriello, S Heltshe, M Rosenfeld, SN Patel Proceedings of the 2012 ACM Conference on ubiquitous computing, 280-289, 2012 | 235 | 2012 |
| Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections KB Hisert, SL Heltshe, C Pope, P Jorth, X Wu, RM Edwards, M Radey, ... American journal of respiratory and critical care medicine 195 (12), 1617-1628, 2017 | 214 | 2017 |
| Restoring cystic fibrosis transmembrane conductance regulator function reduces airway bacteria and inflammation in people with cystic fibrosis and chronic lung infections KB Hisert, SL Heltshe, C Pope, P Jorth, X Wu, RM Edwards, M Radey, ... American journal of respiratory and critical care medicine 195 (12), 1617-1628, 2017 | 195 | 2017 |
| Late diagnosis defines a unique population of long-term survivors of cystic fibrosis DM Rodman, JM Polis, SL Heltshe, MK Sontag, C Chacon, RV Rodman, ... American journal of respiratory and critical care medicine 171 (6), 621-626, 2005 | 173 | 2005 |
| Risk of total and aggressive prostate cancer and pesticide use in the Agricultural Health Study S Koutros, LE Beane Freeman, JH Lubin, SL Heltshe, G Andreotti, ... American journal of epidemiology 177 (1), 59-74, 2013 | 170 | 2013 |
| Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor SL Heltshe, N Mayer-Hamblett, JL Burns, U Khan, A Baines, BW Ramsey, ... Clinical Infectious Diseases 60 (5), 703-712, 2015 | 154 | 2015 |
| Sweat chloride as a biomarker of CFTR activity: proof of concept and ivacaftor clinical trial data FJ Accurso, F Van Goor, J Zha, AJ Stone, Q Dong, CL Ordonez, SM Rowe, ... Journal of Cystic Fibrosis 13 (2), 139-147, 2014 | 118 | 2014 |
| Multiple-breath washout as a lung function test in cystic fibrosis. A cystic fibrosis foundation workshop report P Subbarao, C Milla, P Aurora, JC Davies, SD Davis, GL Hall, S Heltshe, ... Annals of the American Thoracic Society 12 (6), 932-939, 2015 | 115 | 2015 |
| A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic … MW Konstan, G Döring, SL Heltshe, LC Lands, KA Hilliard, P Koker, ... Journal of Cystic Fibrosis 13 (2), 148-155, 2014 | 112 | 2014 |
| Occupational exposure to pesticides and bladder cancer risk S Koutros, DT Silverman, MCR Alavanja, G Andreotti, CC Lerro, S Heltshe, ... International journal of epidemiology 45 (3), 792-805, 2016 | 108 | 2016 |
| GOAL Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network. Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator … SM Rowe, SL Heltshe, T Gonska, SH Donaldson, D Borowitz, D Gelfond, ... Am J Respir Crit Care Med 190 (2), 175-84, 2014 | 87 | 2014 |
| Functional and psychosocial outcomes of older adults after burn injury: results from a multicenter database of severe burn injury MB Klein, DC Lezotte, S Heltshe, J Fauerbach, RK Holavanahalli, ... Journal of Burn Care & Research 32 (1), 66-78, 2011 | 83 | 2011 |
| Use of FEV1 in cystic fibrosis epidemiologic studies and clinical trials: a statistical perspective for the clinical researcher R Szczesniak, SL Heltshe, S Stanojevic, N Mayer-Hamblett Journal of Cystic Fibrosis 16 (3), 318-326, 2017 | 80 | 2017 |
| Heterogeneity in survival in adult patients with cystic fibrosis with FEV1< 30% of predicted in the United States KJ Ramos, BS Quon, SL Heltshe, N Mayer-Hamblett, ED Lease, ... Chest 151 (6), 1320-1328, 2017 | 75 | 2017 |
| Metagenomic evidence for taxonomic dysbiosis and functional imbalance in the gastrointestinal tracts of children with cystic fibrosis O Manor, R Levy, CE Pope, HS Hayden, MJ Brittnacher, R Carr, ... Scientific reports 6 (1), 1-9, 2016 | 74 | 2016 |
| Escherichia coli Dysbiosis Correlates With Gastrointestinal Dysfunction in Children With Cystic Fibrosis LR Hoffman, CE Pope, HS Hayden, S Heltshe, R Levy, S McNamara, ... Clinical infectious diseases 58 (3), 396-399, 2014 | 71 | 2014 |
| Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis SL Heltshe, CH Goss, V Thompson, SD Sagel, DB Sanders, BC Marshall, ... Thorax 71 (3), 223-229, 2016 | 67 | 2016 |
| Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations NE West, VV Beckett, R Jain, DB Sanders, JA Nick, SL Heltshe, ... Journal of Cystic Fibrosis 16 (5), 600-606, 2017 | 65 | 2017 |
| Impact of CFTR modulation on intestinal pH, motility, and clinical outcomes in patients with cystic fibrosis and the G551D mutation D Gelfond, S Heltshe, C Ma, SM Rowe, C Frederick, A Uluer, L Sicilian, ... Clinical and translational gastroenterology 8 (3), e81, 2017 | 64 | 2017 |
